BioTime News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.05.23	Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (Businesswire)
09.05.23	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Businesswire)
04.05.23	Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (Businesswire)
26.04.23	RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration (Businesswire)
18.04.23	Lineage to Present at 2023 AAPS National Biotechnology Conference (Businesswire)
30.03.23	Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium (Businesswire)
20.03.23	RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit (Businesswire)
09.03.23	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (Businesswire)
08.03.23	Ausblick: BioTime informiert über die jüngsten Quartalsergebnisse (finanzen.net)
06.03.23	RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. (Businesswire)
02.03.23	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 (Businesswire)
22.02.23	Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (Businesswire)
08.02.23	Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss (Businesswire)
29.11.22	Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference (Businesswire)
28.11.22	Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Businesswire)
10.11.22	Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (Businesswire)
09.11.22	Ausblick: BioTime veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
03.11.22	Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022 (Businesswire)
31.10.22	Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer (Businesswire)
10.10.22	Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells (Businesswire)
04.10.22	Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa (Businesswire)
03.10.22	Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel (Businesswire)
15.08.22	Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference (Businesswire)
11.08.22	Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (Businesswire)
10.08.22	Ausblick: BioTime präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
04.08.22	Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 (Businesswire)
02.06.22	Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology (Businesswire)
12.05.22	Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (Businesswire)
11.05.22	Ausblick: BioTime veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
05.05.22	Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 (Businesswire)
03.05.22	RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration (Businesswire)
26.04.22	Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022 (Businesswire)
25.04.22	Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness (Businesswire)
13.04.22	Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer (Businesswire)
11.04.22	Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022 (Businesswire)
24.03.22	Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 (Businesswire)
21.03.22	Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss (Businesswire)
14.03.22	RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS (Businesswire)
10.03.22	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Businesswire)
09.03.22	Ausblick: BioTime mit Zahlen zum abgelaufenen Quartal (finanzen.net)
01.03.22	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022 (Businesswire)
24.01.22	Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022 (Businesswire)
20.12.21	Pre-market Movers: SOPA, VRS, ITCI, IMMX, SPRB… (RTTNews)
20.12.21	Why Lineage Cell Therapeutics Is Rising In Pre-market? (RTTNews)
20.12.21	Roche erwirbt Lizenzrechte für experimentelle Augen-Zelltherapie (Dow Jones)
09.11.21	Ausblick: BioTime zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
10.08.21	Ausblick: BioTime legt Zahlen zum jüngsten Quartal vor (finanzen.net)
28.06.21	Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes (Businesswire)
22.06.21	Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing (Businesswire)
17.06.21	Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem® (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	82.24	2.93 %	K V
Part Grp Hldg	1’404.00	1.67 %	K V
CieFinRichemont	170.10	1.10 %	K V
Kuehne+Nagel Int	206.60	0.98 %	K V
Holcim	89.82	0.92 %	K V
ABB	53.58	0.04 %	K V
Givaudan	3’941.00	-0.10 %	K V
Geberit	498.50	-0.46 %	K V
Alcon	80.46	-0.54 %	K V
Sonova Hldg	314.80	-1.16 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu BioTime Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten